175 research outputs found
Economic evaluation of implementation strategies in health care
Economic evaluations can inform decisions about the efficiency and allocation of resources to implementation
strategies? strategies explicitly designed to inform care providers and patients about the best available research
evidence and to enhance its use in their practices. These strategies are increasingly popular in health care,
especially in light of growing concerns about quality of care and limits on resources. But such concerns have hardly
motivated health authorities and other decision-makers to spend on some form of economic evaluation in their
assessments of implementation strategies. This editorial addresses the importance of economic evaluation in the
context of implementation science? particularly, how these analyses can be most efficiently incorporated into
decision-making processes about implementation strategies
Economic value of in vitro fertilization in Ukraine, Belarus, and Kazakhstan
__Abstract__
Background: An economic value calculation was performed to estimate the lifetime net present value of in vitro fertilization (IVF) in Ukraine, Belarus, and Kazakhstan.
Methods: Net lifetime tax revenues were used to represent governmental benefits accruing from a hypothetical cohort of an IVF population born in 2009 using the methodology of generational accounting. Governmental expenses related to this population included social benefits, education and health care, unemployment support, and pensions. Where available, country-specific data referencing official sources were applied
Do the Washington Panel recommendations hold for europe inversigating the relation between quality of life versus work-status, absenteeism and presenteeism
__Abstract__
Background: The question of how to value lost productivity in economic evaluations has been subject of debate
in the past twenty years. According to the Washington panel, lost productivity influences health-related quality of
life and should thus be considered a health effect instead of a cost to avoid double counting. Current empirical
evidence on the inclusion of income loss when valuing health states is not decisive. We examined the relationship
between three aspects of lost productivity (work-status, absenteeism and presenteeism) and patient or social
valuation of health-related quality of life (HRQoL).
Methods: Cross-sectional survey data were collected from a total of 830 respondents with a rheumatic disorder
from four West-European countries. Health-related quality of life was expressed in either the European societal utility
using EQ-5D-3L or the patient valuation using EQ-VAS. The impact of work-status (four categories), absenteeism
(absent from paid work during the past three months), and presenteeism (QQ method) on EQ-5D utilities and VAS
scores was examined in linear regression analyses taking into account demographic characteristics and disease
severity (duration, pain and restriction).
Results: The relationship between work-status, absenteeism or presenteeism and HRQoL was stronger for patient
valuation than societal valuation. Compared to work-status and presenteeism the relationship between absenteeism
and HRQoL was even less explicit. However, results for all measures of lost productivity are only marginally significant
and negligible compared to the influence of disease-related restrictions.
Conclusions: This survey study in patients with a rheumatic disorder in four European countries, does not fully support
the Washington panel’s claim that lost productivity is a significantly related with HRQoL, and this is even more apparent
for absenteeism than for work-status and presenteeism. For West-European countries, there is no reason, to include
absenteeism in the QALY. Findings need to be confirmed in other disease areas
Challenges in modelling the cost effectiveness of various interventions for cardiovascular disease
Objectives: Decision analytic modelling is essential in performing cost-effectiveness analyses (CEAs) of interventions in cardiovascular disease (CVD). However, modelling inherently poses challenges that need to be dealt with since models always represent a simplification of reality. The aim of this study was to identify and explore the challenges in modelling CVD interventions. Methods: A document analysis was performed of 40 model-based CEAs of CVD interventions published in high-impact journals. We analysed the systematically selected papers to identify challenges per type of intervention (test, non-drug, drug, disease management programme, and public health intervention), and a questionnaire was sent to the corresponding authors to obtain a more thorough overview. Ideas for possible solutions for the challenges were based on the papers, responses, modelling guidelines, and other sources. Results: The systematic literature search identified 1,720 potentially relevant articles. Forty authors were identified after screening the most recent 294 papers. Besides the challenge of lack of data, the challenges encountered in the review suggest that it was difficult to obtain a sufficiently valid and accurate cost-effectiveness estimate, mainly due to lack of data or extrapolating from intermediate outcomes. Despite the low response rate of the questionnaire, it confirmed our results. Conclusions: This combination of a review and a survey showed examples of CVD modelling challenges found in studies published in high-impact journals. Modelling guidelines do not provide sufficient guidance in resolving all challenges. Some of the reported challenges are specific to the type of intervention and disease, while some are independent of intervention and disease
Costs of Treating Lymphoproliferative Disorders in Ukraine: a Pilot Evaluation
Chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are two of the most widespread lymphoproliferative disorders among the adult population
of Ukraine and other Central and Western European countries. Considering that pharmaceutical treatment accounts for the major part of medical
expenses in the management of these conditions, the aim of this study was to assess the costs of pharmacotherapy of CLL and MM. The analysis was
performed retrospectively using the results of our own pilot study, in which we examined medical histories of the patients treated at a specialized medical
center in Kiev. The average annual cost of pharmacotherapy of all Ukrainian patients was 340 750 162 RUB for CLL and 89 184 759 RUB for MM. We
found a negative correlation between the patient’s age and the cost of pharmacotherapy
Using meta-regression analyses in addition to conventional systematic review methods to examine the variation in cost-effectiveness results - a case study
REVIEWING TRANSFERABILITY in ECONOMIC EVALUATIONS ORIGINATING from EASTERN EUROPE
__Objectives:__ The aim of this study is to analyze the quality and transferability issues reported in published peer-reviewed English-language economic evaluations based in healthcare settings of the Central and Eastern European (CEE) and former Soviet countries.
__Methods:__ A systematic search of economic evaluations of healthcare interventions was performed for Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Georgia, Turkmenistan, Kazakhstan, Lithuania, the former Yugoslav Republic of Macedonia, Republic of Moldova, Romania, the Russian Federation, Serbia, Slovenia, and Ukraine. The included studies were assessed according to their characteristics, quality (using Drummond’s checklist), use of local data, and the transferability of inputs and results, if addressed.
__Results:__ Most of the thirty-four economic evaluations identified were conducted from a healthcare or payer perspective (74 percent), with 47 percent of studies focusing on infectious diseases. The least frequently and transparently addressed parameters were the items’ stated perspectives, relevant costs included, accurately measured costs in appropriate units, outcomes and costs credibly valued, and uncertainties addressed. Local data were often used to assess unit costs, baseline risk, and resource usage, while jurisdiction-specific utilities were included in only one study. Only 32 percent of relevant studies discussed the limitations of using foreign data, and 36 percent of studies discussed the transferability of their own study results to other jurisdictions.
__Conclusions:__ Transferability of the results is not sufficiently discussed in published economic evaluations. To simplify the transferability of studies to other jurisdictions, the following should be comprehensively addressed: uncertainty, impact of influential parameters, and data transferability. The transparency of reporting should be improved
- …